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Radiation therapy plays an important role in the management of a wide range of cancers.
Besides innovations in the physical application of radiation dose, radiation therapy is likely
to benefit from novel approaches exploiting differences in radiation response between
normal and tumor cells. While ionizing radiation induces a variety of DNA lesions, includ-
ing base damages and single-strand breaks, the DNA double-strand break (DSB) is widely
considered as the lesion responsible not only for the aimed cell killing of tumor cells,
but also for the general genomic instability that leads to the development of secondary
cancers among normal cells. Homologous recombination repair (HRR), non-homologous
end-joining (NHEJ), and alternative NHEJ, operating as a backup, are the major pathways
utilized by cells for the processing of DSBs. Therefore, their function represents a major
mechanism of radiation resistance in tumor cells. HRR is also required to overcome repli-
cation stress – a potent contributor to genomic instability that fuels cancer development.
HRR and alternative NHEJ show strong cell-cycle dependency and are likely to benefit from
radiation therapy mediated redistribution of tumor cells throughout the cell-cycle. More-
over, the synthetic lethality phenotype documented between HRR deficiency and PARP
inhibition has opened new avenues for targeted therapies. These observations make HRR
a particularly intriguing target for treatments aiming to improve the efficacy of radiation
therapy. Here, we briefly describe the major pathways of DSB repair and review their pos-
sible contribution to cancer cell radioresistance. Finally, we discuss promising alternatives
for targeting DSB repair to improve radiation therapy and cancer treatment.
Keywords: DNA double-strand breaks, ionizing radiation, homologous recombination repair, radiosensitization,
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INTRODUCTION
During the past few decades extensive efforts have been made to
improve cancer therapy both by establishing more successful treat-
ment approaches, as well as by developing effective means for early
diagnosis. Despite advances in many fronts, radiation remains one
of the most successful treatment modalities for solid cancers that
is applied to over 50% of all cancers at one stage of their manage-
ment (Delaney et al., 2005; Connell and Hellman, 2009; Ahmad
et al., 2012; Siegel et al., 2012).
Radiation therapy aims to cure cancer by eradicating tumor
cells. The tool of radiation therapy, ionizing radiation (IR), induces
a plethora of DNA lesions, including oxidative base damages,
single-strand breaks (SSBs), and double-strand breaks (DSBs),
which affect the DNA integrity or alter its chemical nature (Ward,
1990). Among these lesions, DSBs have been reported to trigger the
most detrimental effects on genome stability, and have been iden-
tified as the main contributors to IR induced cell killing through
the formation of chromosomal aberrations (Povirk, 2006; Iliakis
et al., 2007).
However, while treating tumors, radiation also always reaches
normal tissue risking the development of side effects and the
All used abbreviations are indicated in Table A1 in Appendix.
generation of secondary malignancies. As a result, the central chal-
lenge of radiation therapy is to maximize tumor cell killing and
minimize at the same time the normal tissue side effects. Modern
conformal, intensity-modulated radiation therapy approximates
this goal by optimizing radiation dose deposition between tumor
and the surrounding normal tissue. Further improvements are
possible using biological approaches that exploit differences in
radiation response between normal and tumor cells and aim at
protecting normal cells while maximizing the radiation response
of tumor cells. Thus, radiosensitizing agents offer a benefit when
radiosensitization occurs rather specifically in cancer cells.
The observation that components of the homologous recom-
bination repair (HRR) pathway are aberrantly expressed in many
tumors (Connell et al., 2006; Klein, 2008; Miyagawa, 2008; Tennst-
edt et al., 2012) and the correlation between tumor radiore-
sistance, poor prognosis, and increased HRR activity make this
repair pathway an attractive target with potential for differential
responses. This view is further reinforced by the highly selective
cell killing exerted by PARP-inhibitors in HRR deficient cells. How-
ever, similar conclusions have been also drawn for other DSB repair
pathways (see below).
In the present review, we give a brief overview of the current
state of knowledge in DSB repair and outline how this information
may be harnessed to improve radiation therapy.

























































Mladenov et al. HRR as a target of radiotherapy
THE DSB REPAIR ARSENAL
Double-strand breaks are generated randomly in the genomic
DNA after exposure of cells to IR, or after treatment with
radiomimetic drugs, DNA replication inhibitors, or topoisomerase
poisons (Povirk, 2012). DSBs also arise randomly throughout the
genome from reactive oxygen species generated as byproducts of
the cellular metabolism, as well as from errors during DNA replica-
tion, the improper elimination of which may contribute to cancer
progression (Vilenchik and Knudson, 2003).
Notably, DSBs are also generated in a programed manner as
part of important cellular processes, such as the maturation of
lymphoid cells or gametogenesis during meiosis (Keeney et al.,
1997; Panizza et al., 2011; Schatz and Swanson, 2011). In both
cases specific enzymes are involved in the production of DSBs
that are generated under stringent control, mostly at pre-defined
locations in the genome.
In cancer therapy, the lethal effects of randomly induced DSBs
are exploited to eliminate actively proliferating tumor cells. How-
ever, since induction of DSBs by IR appears comparable in nor-
mal and tumor cells, specificity of IR-toxicity to cancer cells is
likely to rely either on their increased proliferative activity, or on
defects in the processing of DSBs. Indeed, tumor cells frequently
exhibit defects in various DNA repair pathways, which generate
opportunities for enhanced treatment efficacy.
Two mechanistically and genetically distinct pathways con-
tribute to the elimination of DSBs from the genome of higher
eukaryotes: non-homologous end-joining (NHEJ), which can
be subdivided in DNA-PKcs dependent NHEJ (D-NHEJ) and
alternative/backup NHEJ (B-NHEJ) (see below), and HRR.
DSB REPAIR BY D-NHEJ
D-NHEJ catalyzes a simple rejoining reaction between two DNA
ends irrespective of their origin (Lieber, 2010) and does not require
homology at the ends or elsewhere; these facts render NHEJ oper-
ational throughout the cell-cycle. Indeed, D-NHEJ is active in all
phases of the cell-cycle, where it removes DSBs from the genome
with similar efficiency, but possesses only limited functionality
for single-ended DSBs that arise during replication (Metzger and
Iliakis, 1991; Rothkamm et al., 2003; Helleday et al., 2007).
The key steps of the classical form of NHEJ are summarized in
Figure 1. The high affinity of KU heterodimer for free DNA ends
(1–10× 10−9 M, depending on the DNA end-structures), makes it
the ultimate initiation factor of this repair pathway (Arosio et al.,
2002). Indeed, it has been shown that the two subunits of the
KU heterodimer, KU70 and KU80, which form an asymmetric
toroid structure, are perfectly designed to bind and threat on free
DNA ends (Figure 1). The binding of KU to DSBs blocks nucle-
olytic processing of DNA ends, which is required for the initiation
of other DSB repair pathways (see below). However, despite its
reported lyase activity (Roberts et al., 2010; Strande et al., 2012),
the essential role of KU during NHEJ is to recruit the catalytic
subunit of the DNA-PKcs, which dominates and drives the repair
of DSBs in cells of higher eukaryotes. Hence, this form of repair
has also been termed D-NHEJ (Mladenov and Iliakis, 2011).
The binding and dimerization of DNA-PKcs immobilizes the
two DNA ends and thus facilitates the rejoining reaction (Meek
et al., 2004). The interactions of DNA-PKcs with KU, as well as the
FIGURE 1 | Schematic representations of DSB repair by
non-homologous end-joining. The process is initiated by the binding of
KU heterodimer to the DNA ends, which then recruits DNA-PKcs to form an
active DNA-PK holoenzyme. DNA-PK activation helps the recruitment of
multiple proteins involved in the limited DNA end-processing (Artemis, pol
µ, pol λ, and TDK) required to generate ligatable DNA ends. Ligation is
mediated exclusively by the LIG4/XRCC4 complex and is assisted by the
ligation mediator XLF. At the end of this process the DNA integrity at the
break is restored, but the DNA sequence at the junction may be altered.
binding of DNA-PKcs to the DNA result in almost 10-fold increase
in DNA-PKcs kinase activity. Accumulating evidence shows that
a variety of proteins specifically involved in D-NHEJ, or generally
in the DNA damage response (DDR), are phosphorylation targets
of DNA-PKcs. However, interference with these phosphorylations
is often without effect in DSB repair, and the only modification,
which severely affects the end-joining efficiency, is elimination of
DNA-PKcs auto-phosphorylation (Meek et al., 2004). Depending
on the nature of DNA lesions, DNA-PKcs can be phosphorylated
at multiple residues, which is a prerequisite for its dissociation
from the damaged sites and the recruitment of other repair factors
(Figure 1).
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Since DSBs generated by IR bear damaged nucleotides at their
ends, a limited end-processing by nucleolytic enzymes or DNA
polymerases (pol µ and pol λ) is required to generate ligatable
ends (Weterings and Chen, 2008) (Figure 1). As a result, sequence
changes at the junctions generated by NHEJ are possible and there-
fore mutations likely. Furthermore, since D-NHEJ rejoins DNA
ends indiscriminately, it can lead to translocations and other chro-
mosomal rearrangements that are hallmarks of genomic instabil-
ity. It is therefore quite surprising that despite such limitations,
cells of higher eukaryotes extensively utilize D-NHEJ to remove
DSBs from their genome.
The final step during D-NHEJ is mediated by a highly special-
ized ligation complex consisting of DNA Ligase 4 (LIG4) and the
X-ray cross complementing 4 (XRCC4) protein (LIG4/XRCC4)
(Figure 1). Assisted by the auxiliary factor XLF (Cernunos),
LIG4/XRCC4 mediates ligation that results in fast and efficient
restoration of DNA integrity, albeit often at the cost of sequence
information loss.
DSB REPAIR BY B-NHEJ
During the past decade a second pathway for rejoining of bro-
ken DNA molecules on the basis of NHEJ was discovered and
is presently intensively investigated. As with D-NHEJ this repair
pathway also lacks means to restore sequence information at the
DSB, and as we will discuss later, it also has a higher probability to
join unrelated DNA ends.
Initially, analyses of DSB repair using pulse-field gel elec-
trophoresis (PFGE) in cells deficient in components of D-NHEJ,
revealed a robust repair activity that was unrelated to HRR (see
below) and reflected a different form of DNA end-joining instead
(DiBiase et al., 2000; Singh et al., 2009). This alternative form
of DSB repair efficiently substituted for D-NHEJ, but appeared
to have backup functions, coming to the fore mainly after fail-
ure of D-NHEJ; therefore the term B-NHEJ was proposed for
this repair pathway (Iliakis, 2009; Mladenov and Iliakis, 2011).
Failures of D-NHEJ, which allow function of B-NHEJ, can also
occur locally at a specific DSB, even in repair proficient cells, or
globally in cells with mutations in genes encoding for D-NHEJ
factors, or after treatment with DNA-PKcs inhibitors. Subsequent
work documented the function of such alternative pathways of
NHEJ in several processes involving the formation of DSBs, such
as V(D)J recombination and class switch recombination (Corneo
et al., 2007), and were also implicated in cancer formation (Simsek
et al., 2011).
Several enzymatic activities have been implicated in this repair
pathway, which is now considered to be distinct from D-NHEJ and
which may even be further subdivided into sub-pathways (Wang
et al., 2005; Rosidi et al., 2008; Zha et al., 2009; Lee-Theilen et al.,
2011; Mladenov and Iliakis, 2011).
A major protein implicated in B-NHEJ is poly (ADP-ribose)
polymerase 1 (PARP-1), which plays a main role in the repair of
SSBs (see below) and which may effectively compete with KU
heterodimer for DNA end-binding (Wang et al., 2006). It has
been reported that PARP-1 facilitates the repair of DSBs by B-
NHEJ, while another member of the PARP family, PARP-2 strongly
suppresses it (Robert et al., 2009) (Figure 2). It has also been
reported that B-NHEJ benefits from microhomology at the break
FIGURE 2 | Repair of DSBs by B-NHEJ. This pathway remains
incompletely characterized. Factors implicated include PARP-1, the MRN
complex, CtIP, and WRN. Ligation is mediated by LIG3 or LIG1. The
restoration of DNA integrity through this repair pathway is also associated
with sequence information loss at the junction, and more importantly, by
increased risk of joining unrelated DNA ends to generate translocations and
other genomic rearrangements.
sites, which may be best found if the DNA ends become resected.
Indeed, MRE11 and C-terminal binding protein 1 interacting pro-
tein (CtIP), both involved in DNA end-resection during HRR (see
below), were found to facilitate B-NHEJ (Zha et al., 2009; Lee-
Theilen et al., 2011) (Figure 2). However, it is important to point
out that B-NHEJ does not exhibit a strict requirement for micro-
homology, therefore, this repair pathway should not be considered
as a microhomology dependent (Mansour et al., 2010).
Backup NHEJ, like D-NHEJ, is active in all phases of the
cell-cycle, but its activity is significantly potentiated during S
and G2, probably due to the increased activity of DNA end-
resection enzymes in these cell-cycle phases. Therefore, it is
likely that B-NHEJ also operates as a backup to HRR in the G2
and S-phases of the cell-cycle (see below). Notably, B-NHEJ is
severely compromised when D-NHEJ deficient cells enter a plateau
phase of growth or are deprived of serum (Singh et al., 2011,
2012). An intriguing and still unexplained observation is that this
effect is not observed in DNA-PKcs deficient cells (Singh et al.,
2011).
A ligation activity finalizing B-NHEJ is DNA Ligase 3 (LIG3), a
versatile ligase, which in complex with XRCC1 also participates in
the repair of SSBs and DNA base damages (Wang et al., 2005; Della-
Maria et al., 2011) (Figure 2). Assisted by its unique structural
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properties, LIG3 ensures the ligation of both DNA strands during
DSB repair (Ellenberger and Tomkinson, 2008). However, despite
reports to the opposite (Audebert et al., 2004), the role of XRCC1
in LIG3 function during B-NHEJ remains unclear (Della-Maria
et al., 2011; Boboila et al., 2012). Recent evidence also implicates
DNA Ligase 1 (LIG1) in B-NHEJ (Simsek et al., 2011; Paul et al.,
2013). Thus, it appears that while LIG4 is specifically dedicated to
D-NHEJ, LIG1, and LIG3 can efficiently support B-NHEJ.
Furthermore, interesting regulatory proteins were implicated
in B-NHEJ. The Werner syndrome helicase (WRN), together
with LIG3, was found upregulated in chronic myelogenous
leukemia (CML), where several D-NHEJ activities are suppressed.
Under these conditions WRN and LIG3 form a stable complex,
which is recruited to DSBs, thus activating the ligation process
(Sallmyr et al., 2008) (Figure 2). Moreover, a form of error-prone
repair, with characteristics of single-strand annealing (SSA), was
described in many myeloproliferative disorders, which are char-
acterized by the formation of oncogenic fusion tyrosine kinases,
including BCR/ABL, TEL/ABL, TEL/JAK2, and TEL/PDGFBR
(Cramer et al., 2008). This form of repair contributes to the
accumulation of intrachromosomal deletions and translocations,
a hallmark of the B-NHEJ repair pathway; therefore it has been
suggested that it might be a sub-pathway of alternative DSB repair
mechanisms (Mladenov and Iliakis, 2011).
Another factor implicated in B-NHEJ is histone H1, which
enhances the rejoining activity of LIG3 presumably by facilitating
the synapsing of DNA molecules (Rosidi et al., 2008).
Backup NHEJ is much slower than D-NHEJ and is highly
error-prone causing translocations and other genomic rearrange-
ments with high probability. Moreover, a high number of B-NHEJ
associated genetic rearrangements have been observed in chro-
mosomal translocations associated with both spontaneous and
therapy-related cancers (Greaves and Wiemels, 2003). Thus, B-
NHEJ-derived mutations appear to be associated with cancer
development and may support tumor progression – particularly
when classical NHEJ or HRR are compromised (Bennardo et al.,
2008). It is therefore conceivable that activation of B-NHEJ fuels
the evolution of cancer, and that it might also serve as target in
specialized cancer therapies.
DSB REPAIR BY HRR
The second approach to DSB repair, HRR, requires intact homolo-
gous DNA sequences to remove DSBs and to faithfully restore the
DNA sequence in their vicinity (San Filippo et al., 2008). One form
of HRR (described in Figures 3 and 4) utilizes the sister chromatid
as a donor for homologous sequence and is therefore active only
in S and G2 phases of the cell-cycle (Onn et al., 2008; San Filippo
et al., 2008). In principle, HRR could also be carried out in diploid
cells during the G1 phase of the cell-cycle using the homologous
chromosome as template. However, the distinct compartmental-
ization of the nuclear domains of homologous chromosomes make
required interactions unfavorable; in fact, it is thought that HRR
is actively suppressed in G1 cells in an effort to prevent loss of het-
erozygosity (LOH) (Paques and Haber, 1999; Aylon and Kupiec,
2004).
DNA end-resection is a necessary requirement for the initia-
tion of HRR, as a long single-stranded 3′-DNA overhang has to be
FIGURE 3 | Schematic overview of the early steps of HRR. The formation
of pre-synaptic Rad51 nucleoprotein filament. The initiation steps and the
full sequence of events contributing to the faithful restoration of DNA
sequence at the DSB are explained in the text.
formed in order to start homology search (West, 2003). Activities
implicated in diverse aspects of end-resection include the MRE11-
RAD50-NBS1 (MRN complex), the CtIP, as well as Exonuclease 1
(EXO1), DNA2, and the Bloom’s syndrome helicase (BLM) (see
below) (Figure 3). In order to execute their function during HRR
initiation, the MRN complex is quickly recruited to DSB, where
it cooperates with CtIP to promote end-resection (Sartori et al.,
2007; Kousholt et al., 2012; Leslie, 2013). It is thought that end-
resection defines the point of no-return in the decision to process
a DSB by HRR. Therefore, the formation of single-stranded DNA
regions is frequently used as a surrogate for ongoing HRR. How-
ever, as noted above, it is also possible that HRR abrogation after
resection will shunt DSBs to B-NHEJ (we will return to this point
below).
The combined action of DNA end-resection enzymes results in
the formation of single-stranded DNA, decorated by the replica-
tion protein A (RPA) (Figure 3). RPA is a heterotrimeric complex,
comprising of RPA70, RPA32, and RPA14, which exhibits high
affinity for binding to ssDNA regions, such as those formed during
DNA replication and occasionally during repair. In the subsequent
steps of HRR, RPA is replaced by RAD51 recombinase, which
forms a right-handed pre-synaptic RAD51 nucleoprotein filament
on the DNA (Figure 3). The replacement of RPA by RAD51
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FIGURE 4 | Late steps in DSB repair by HRR. The formation of D-loop structure and two sub-pathways are depicted (see text for more details).
requires the activity of mediator proteins, such as Breast cancer
susceptibility gene 2 (BRCA2) and a group of five RAD51 paralogs
(RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3), which share
20–30% sequence similarity with the RAD51 recombinase (West,
2003).
The exact function of the RAD51 paralogs remains elusive, but
there is evidence that they may form distinct complexes, which
facilitate the formation and stabilization of the RAD51 filament
(Masson et al., 2001; Forget et al., 2004; Suwaki et al., 2011); they
also exhibit some specific functions in telomere maintenance and
probably during DDR (Tarsounas et al., 2004; Badie et al., 2009).
The accumulation of RAD51 monomers at the damaged sites and
the formation of a RAD51 nucleoprotein filament, can be visual-
ized by immunofluorescence microscopy as distinct sub-nuclear
RAD51 foci, which are routinely utilized to investigate DSB repair
by HRR (Haaf et al., 1995).
The formation of RAD51 nucleoprotein filament is regulated
by specific enzymatic activities, which displace RAD51 mole-
cules or facilitate their association. The newly characterized PARI
protein together with a RECQL5 helicase may act as a negative
regulator of RAD51 filament formation (Karpenshif and Bern-
stein, 2012) (Figure 4). Moreover, the “anti-recombinase” pro-
teins BLM and RTEL1, could also have negative impact on the
already formed RAD51 filament, thus facilitating its dissociation
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when HRR is disadvantageous (Karpenshif and Bernstein, 2012)
(Figure 4).
In the subsequent steps of HRR, the RAD51 nucleoprotein fila-
ment invades the intact double-stranded DNA molecule to search
for homologous sequences and form a structure termed displace-
ment loop (D-loop). When homology is found (synapsis) DNA
synthesis will start elongating the 3′-end of the invading strand
(Figure 4). For elongation to commence, RAD51 in the synaptic
complex has to be removed from the very 3′ tip of the invading
strand to reveal the 3′-OH group for priming; this reaction is facili-
tated by RAD54 and its interacting partner RAD54B (Li and Heyer,
2009). HRR can take several different routes from this point. Fre-
quently, elongation of the invading 3′-end can continue over a
limited distance, followed by displacement of the newly synthe-
sized stretch and re-ligation with the original DNA end resulting
in the repair of the DSB (synthesis-dependent strand annealing;
SDSA) (Figure 4). This is the most frequent event during DSB
repair in cells of higher eukaryotes and is equivalent to gene con-
version. Alternatively, second end-capture can occur, leading to
the formation of a double Holliday junction (dHJ) (DSB repair;
DSBR) (Figure 4). Depending on the resolution of the dHJ by
specialized resolving enzymes, GEN1 and possibly MUS81/EME1,
this branch of HRR will result in either crossover or non-crossover
(gene conversion) outcomes (Constantinou et al., 2002; Wu and
Hickson, 2003; Ip et al., 2008) (Figure 4).
First reported in yeast and later in higher eukaryotes, recom-
bination events between areas of homology present in the same
DNA molecule could be observed. This process is known as SSA
(Ivanov et al., 1996). When this pathway is used to repair a DSB it
leads to loss of the DNA segment between the regions of homol-
ogy and therefore it is considered as mutagenic. The role of SSA
in the repair of randomly induced DSBs, such as those generated
by IR, remains uncharacterized and is likely to be small. However,
there is evidence for a correlation between increased formation of
chromosomal aberrations and SSA in cells of myeloproliferative
disorders expressing oncogenic fusion tyrosine kinases (Cramer
et al., 2008).
Finally, in yeast another mode of HRR – termed break induced
replication (BIR) – has been described, that steps into action
when one sided DSBs are formed. It is characterized by the ini-
tiation of replication through the formation of a replication fork
that replicates the entire chromosome past the DSB (Fan et al.,
2004). As a result of this peculiarity, BIR can cause extensive LOH
(Llorente et al., 2008). However in mammalian cells the action of
BIR remains to be demonstrated.
REGULATION OF HRR – WAYS TO MODULATE THE REPAIR
PATHWAY CHOICE
Some competition between the DSB repair processes described
above is often considered likely (Sonoda et al., 2006; Shrivastav
et al., 2008). Although the basis of DSB repair pathway choice in
cells of higher eukaryotes remains largely elusive, it is clear that one
important determinant is the position of the cell in the cell-cycle –
particularly for HRR (see above). In addition to its requirement for
a sister chromatid, HRR is also regulated throughout the cell-cycle
in at least two ways: (1) Cell-cycle dependent regulation of the
expression levels of proteins involved in HRR and (2) through
cyclin dependent kinase (CDK)-dependent phosphorylation of
some of its components.
Expression levels of RAD51, Breast cancer susceptibility gene
1 (BRCA1), BRCA2, BLM, and CtIP are all regulated throughout
the cell-cycle (Flygare et al., 1996; Yamamoto et al., 1996; Wang
et al., 1997; Dutertre et al., 2000; Yu and Chen, 2004; Shrivastav
et al., 2008). The respective transcripts and/or proteins are present
at low levels in G1 and are hardly detectable or completely absent
in non-dividing, G0 cells. Their expression begins with the start
of DNA replication and increases further with the progression of
cells through S.
One example of CDK-mediated regulation of HRR is the phos-
phorylation of Ser-3291 of BRCA2, which counteracts the inter-
action with RAD51 and thereby negatively regulates HRR activity
(Esashi et al., 2005) (Figure 5). Another regulatory CDK-mediated
phosphorylation occurs at Ser-432 of NBS1 (Figure 5), which is
believed to act as a primary sensor of DSBs. Phosphorylation of
Ser-432 on NBS1 stimulates the conversion of DSBs into substrates
for HRR in a MRN-dependent manner (Falck et al., 2012).
Although MRE11, another member of the MRN complex, can
act as a nuclease and is involved in facilitating resection of ends at
sites of DSBs, the formation of extensive ssDNA regions seems to
be carried out by other nucleases like EXO1 and possibly DNA2
(Bolderson et al., 2010; Eid et al., 2010; Grabarz et al., 2012;
Tomimatsu et al., 2012) (Figure 3) and is facilitated by CtIP and
RECQ family members like BLM (Gravel et al., 2008; Mimitou and
Symington, 2008; Huertas, 2010).
CtIP not only interacts with the MRN complex, but also with
BRCA1 and this interaction is promoted by CDK dependent phos-
phorylation of CtIP on Ser-327 in S/G2, providing yet another
example for cell-cycle regulation of HRR (Yu and Chen, 2004)
(Figure 5). CtIP is also polyubiquitinylated in a BRCA1 dependent
manner, without being targeted for proteasomal degradation (Yu
et al., 2006). However, these are not the only cell-cycle dependent,
regulatory modifications CtIP is subjected to. Phosphorylation of
CtIP on Thr-847 by CDKs is required for efficient end-resection,
and non-phosphorylatable mutants of this site are defective in
end-resection, while phospho-mimicking mutants show resection
even in the absence of CDK activity (Huertas and Jackson, 2009).
Moreover, it has been previously reported that CtIP is phospho-
rylated at Ser-664/745 by the Ataxia telangiectasia mutated (ATM)
protein kinase, which plays an important role during DSB repair by
homologous recombination (Li et al., 2000). Recently, this obser-
vation was extended using Ser-664/745-Ala (phosphomutant) and
Ser-664/745-Glu (phospho-mimicking) forms of CtIP fused to
GFP; it was thus found that ATM is directly engaged in DNA end-
resection by activating CtIP via phosphorylation at Ser-664/745
(Shibata et al., 2011).
Although various models emerge as to how HRR is regulated
throughout the cell-cycle, the question of choice for a particular
repair pathway for each DSB remains poorly understood. There
is however, evidence for crosstalk between HRR and NHEJ and
it has been reported that DNA-PKcs, ATM, and ATM and Rad3
related (ATR) (in a CHK1/2 independent manner) collaborate
to dissociate a p53/RPA-complex by phosphorylating both of its
components (Serrano et al., 2012) (Figure 5). Notably, abrogation
of these phosphorylations impairs HRR.
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FIGURE 5 | Post-translational modifications and interactions possibly
involved in DSB repair pathway choice and HRR modulation. A network
of proteins controls HRR and is regulated by cell-cycle dependent
post-translational modifications. Cell-cycle regulation primarily relies on
Cyclin/CDK dependent phosphorylation events. Regulation in response to
DNA damage primarily relies on the activities of ATM, ATR, and DNA-PKcs.
Control of end-resection plays a central role in this regulation. Resected DNA
decorated with heterotrimeric RPA complexes forms a platform for activation
of ATR. The schematic focuses on interactions/modifications implicated in the
regulation of HRR.
A large number of proteins are subjected to post-translational
modifications (PTMs) that are elicited by DNA damage or replica-
tion stress. We will focus on a small selection of PTMs of proteins
that either play a central role in HRR, or exert regulatory functions
at key HRR steps.
As mentioned above, CtIP is critical in the regulation of end-
resection and is itself post-translationally modified in several
ways. Also EXO1, one of the major nucleases implicated in DNA
end-resection, has been shown to be phosphorylated at mul-
tiple sites. Phosphorylation of EXO1 at Ser-714 by ATM, for
example, is required for the recruitment of RAD51 to sites of
DSBs (Matsuoka et al., 2007; Bolderson et al., 2010) (Figure 5).
Interestingly, this phosphorylation seems to attenuate the nucle-
ase activity of EXO1, suggesting that it might protect from
over-resection.
Another level of regulation of end-resection involves p53 bind-
ing protein 1 (53BP1) and BRCA1. Interestingly loss of 53BP1 on
top of BRCA1 deficiency restores a resistant phenotype in these
radiosensitive cells (“synthetic viability”) (Bouwman et al., 2010;
Bunting et al., 2010). This has led to a model in which 53BP1
inhibits initiation of DNA end-resection and thus favors the repair
by NHEJ. This inhibition is regulated in a negative way by BRCA1
and thus, loss of BRCA1 results in persistent inhibition of end-
resection, which can be abolished by removal of 53BP1 (Aly and
Ganesan, 2011). A number of very recent publications have now
implicated the protein RIF1 as the major downstream effector
of the end-protecting function of 53BP1 (Chapman et al., 2013;
Di Virgilio et al., 2013; Escribano-Diaz et al., 2013; Zimmermann
et al., 2013). One of these studies also found a cell-cycle dependent
inhibitory function of 53BP1 on BRCA1 accumulation at DSB in
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G1 (Escribano-Diaz et al., 2013), which could account for HRR
suppression in G1.
The ssDNA generated during resection is immediately covered
with RPA. The middle subunit of RPA (RPA32/RPA2) is a target for
multiple PTMs, which may have important roles in the subsequent
steps of HRR (Figure 5). It has been shown that hyperphospho-
rylation of RPA32 is required for RAD51 recruitment in response
to replication stress induced by hydroxyurea (HU); however such
dependencies were not identified after IR or endonuclease induced
DSBs (Shi et al., 2010).
Phosphorylations are not the only form of PTMs induced by
DNA damage. Besides the well-known waves of ubiquitylation
mediated by the E3-ubiquitin-ligases RNF8 and RNF168, modifi-
cation with small ubiquitin like modifiers (SUMO) also occurs in
response to DNA breaks. RPA70 is sumoylated on at least two sites
in vivo, but this modification is suppressed by a constitutive inter-
action of the SUMO-specific protease SENP6 (Dou et al., 2010).
In response to replication associated DSBs this interaction is abro-
gated, which allows sumoylation of RPA70 that promotes HRR
(Dou et al., 2010). It has also been reported, that the ubiquitin-
ligase activity of BRCA1 depends on its sumoylation (Morris
et al., 2009). For the BLM helicase multiple sites of sumoylation
have been documented as well and shown to influence its nuclear
localization and possibly to act as switches shifting BLM-activity
between pro- and anti-recombinogenic functions (Eladad et al.,
2005; Ouyang et al., 2009).
Upon formation of a RAD51 coated ssDNA the stability of this
nucleoprotein filament is critical for the execution of HRR. In
mammalian cells helicases like BLM or RECQ5 have been shown
to dismantle RAD51 nucleoprotein filaments (Bugreev et al., 2007;
Hu et al., 2007) (Figure 4). Very recently it was shown that the heli-
case domain containing protein PARI suppresses unscheduled and
inappropriate HRR at replication forks in human and chicken cells
(Moldovan et al., 2012) (Figure 4). This function is mediated by
its interaction with PCNA and might be analogous to the function
of Srs2 in yeast.
RAD51 itself can also be post-translationally modified in sev-
eral ways. Following replication stress, RAD51 is phosphorylated
in a CHK1 dependent manner on Thr-309 (Sorensen et al., 2005),
and also by the c-ABL tyrosine kinase on Tyr-315, which stabi-
lize association of RAD51 with chromatin (Shimizu et al., 2009)
(Figure 5). Two additional phosphorylations of RAD51 that occur
in a cell-cycle and DNA damage dependent manner have been
recently reported: RAD51 is phosphorylated on Ser-14 by PLK1
which licenses phosphorylation of Thr-13 by CK2 (Yata et al.,
2012) (Figure 5). Phosphorylation of Thr-13 leads to direct bind-
ing of RAD51 to NBS1, which facilitates its recruitment to sites of
DNA damage (Yata et al., 2012).
It is evident from the outline above that the cell-cycle regu-
lation of HRR has different levels and is likely to be complex.
Identification of these modifications and characterization of their
functional significance is likely to have important implications to
our understanding of repair pathway choice.
REGULATION OF HRR BY TYROSINE KINASE SIGNALING
Besides the above described intrinsic cell-cycle dependent regu-
latory processes, there is evidence for additional regulatory levels
modulating repair of DSBs. An important example is the BCR-ABL
fusion tyrosine kinase, a hallmark of CML (Skorski, 2012). The
non-mutated c-ABL protein is activated by DNA-PKcs and ATM
in response to genotoxic stress (Kharbanda et al., 1995; Baskaran
et al., 1997). There are reports suggesting that the constitutively
active fusion protein contributes to drug resistance, stimulates
HRR, and promotes ectopic recombination events, through either
up-regulation of RAD51 levels and/or direct phosphorylation of
RAD51 on Tyr-315 (Slupianek et al., 2001, 2002, 2011; Skorski,
2002; Nowicki et al., 2004) (Figure 5).
Up-regulation of mutagenic SSA (see above) by BCR-ABL has
also been reported, and BCR-ABL stimulated expression of CtIP
and increased DNA end-resection have been suggested as a mech-
anism (Cramer et al., 2008; Fernandes et al., 2009; Salles et al.,
2011). Notably, HRR is negatively regulated by the normal form
of c-ABL in irradiated cells by a phosphorylation of RAD51 on Tyr-
54 (Yuan et al., 1998) (Figure 5). Another study shows that Rad51
is phosphorylated on both Tyr-315 and Tyr-54 by c-ABL and that
these phosphorylations are sequential, with the phosphorylation
of Tyr-315 stimulating phosphorylation of Tyr-54 (Popova et al.,
2009). Thus,c-ABL may fine-tune recombination repair by balanc-
ing activating and inhibitory RAD51 phosphorylations, whereas
the constitutively active BCR-ABL protein may cause its hyper-
activation with mutagenic consequences. Interestingly, it has been
reported, that in ABL-positive CML cells, there is also a shift toward
more mutagenic NHEJ repair processes. Sallmyr et al. found LIG4
and Artemis to be down-regulated in these cells, while LIG3 was
upregulated. Since in these cells error-prone NHEJ was observed,
the authors concluded that the activity of B-NHEJ was enhanced
(Brady et al., 2003; Sallmyr et al., 2008).
While the regulatory influence of the ABL kinase on DSB repair
has been mainly linked to DDR responses mediated by DNA-PKcs
and ATM, there are also examples of modulation of DSB repair
through receptor tyrosine kinases activated by their natural extra-
cellular ligands. Over the last 15 years, evidence has accumulated
that overexpression and/or mutation of the EGF receptor (EGFR)
is associated with resistance to chemo- and radiotherapy (Chen
and Nirodi, 2007; Dittmann et al., 2010; Toulany and Rodemann,
2010).
While EGFR is known to exert a cytoprotective action through
the activation of cell survival and proliferation pathways, a large
body of evidence also implicates EGFR signaling in DSB repair. In
glioblastomas, brain tumors characterized by resistance to chemo-
and radiotherapy, the EGFR gene is amplified in 50% of the cases
and a truncated variant – EGFRvIII – is frequently over expressed.
Mukherjee et al. (2009) showed that the expression of this con-
stitutively active EGFR variant confers radioresistance through
activation of PI3K-AKT signaling that enhances DSB repair.
In another study the authors showed by scoring γ-H2AX
foci that activation of EGFR signaling by its natural ligand EGF
enhanced the overall capacity of cells to repair DSBs (Kriegs et al.,
2010). Conversely inhibition of EGFR signaling by Erlotinib or
Cetuximab reduced DSB repair. The authors found that EGFR
activation increased NHEJ, possibly through enhanced MAPK sig-
naling. Another study from the same group showed a positive
effect of EGFR activation on HRR (Myllynen et al., 2011). This
observation is in agreement with work reported by Golding et al.
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(2009) who demonstrated up-regulation of both NHEJ and HRR
by EGFRvIII with assays utilizing appropriate, chromosomally
integrated reporter constructs.
Several reports also indicate an interference of Imatinib,
Erlotinib, and other tyrosine kinase inhibitors (Chinnaiyan et al.,
2005; Li et al., 2008; Choudhury et al., 2009; Zhao et al., 2011;
Medova et al., 2012; Qiao et al., 2013) with HRR. These results
confirm the potential impact of these signaling proteins on DSB
repair and highlight their importance as targets for cancer therapy.
DSB REPAIR DEFICIENCY AND CARCINOGENESIS
The observation that in many cancer cells the DDR is impaired
emphasizes the connection between DSB repair defects and car-
cinogenesis and generates opportunities for cancer treatment.
Indeed, various forms of cancer present with mutations or show
alterations in the expression of genes encoding proteins involved
in DNA metabolism (Connell et al., 2006; Klein, 2008; Miya-
gawa, 2008; Tennstedt et al., 2012). Furthermore, among cancers,
the activities of certain repair proteins fluctuate, from complete
suppression to strong up-regulation, which necessarily modulates
their response to DNA damaging agents. These observations sug-
gest that optimization of cancer therapy will benefit from in-depth
analysis of the status of the DDR apparatus in each individ-
ual tumor and an adaptation of the treatment strategy to this
information.
More specifically, a strong correlation between increased
genomic instability, DNA repair defects, and cancer predisposition
has been documented in cells isolated from individuals carrying
germ line mutations in BRCA1 or BRCA2 genes (O’Donovan and
Livingston, 2010; Roy et al., 2012). The BRCA1 and BRCA2 muta-
tions increase the susceptibility to breast or ovarian cancer, and it
has been estimated that the probability of developing these forms
of cancer is between 30 and 80% in individuals carrying hetero-
or homozygous mutations in these genes (Brody and Biesecker,
1998).
The breast cancer associated gene 1 (BRCA1) was identified
in 1990 (Walsh and King, 2007) and was cloned a few years later
(Miki et al., 1994). Biochemical and structural analyses of human
BRCA1 protein revealed an N-terminal RING domain possessing
E3-ubiquitin-ligase activity and a C-terminal BRCT domain, inter-
acting with proteins phosphorylated on serine within the S-X-X-F
motif. BRCA1 consists of 1863 amino acids and plays an impor-
tant role in maintaining genome integrity through its functions in
DNA repair (Rajagopalan et al., 2010; Roy et al., 2012) To become
a functional E3-ubiquitin-ligase, the RING domain of BRCA1
acts in concert with BRCA1-associated RING domain 1 protein
(BARD1), and this complex is involved in the ubiquitylation of
CtIP (see above). Despite controversial studies, assigning criti-
cal functions for BRCA1 in NHEJ and nucleotide excision repair
(NER), mounting evidence implicates BRCA1 as a key regulator
of HRR (Jasin, 2002; Roy et al., 2012).
The direct recruitment of BRCA1 to DSBs is mediated by its
interaction with Abraxas-RAP80 macro-complex, which binds to
ubiquitylated proteins, particularly histones (Wang et al., 2007).
Once recruited to DSBs, the main regulatory function of BRCA1 is
to conscript and activate the end-resection promoting factor CtIP
(Yun and Hiom, 2009). However, BRCA1 is not only implicated in
HRR by its role in end-resection,but also due to its indirect interac-
tion with BRCA2, which is mediated by the PALB2 protein (Zhang
et al., 2009). Indeed, heterozygous mutations of the latter protein
are also associated with predisposition to breast and pancreatic
cancers (Popova et al., 2009). This interaction directly connects
BRCA1 to HRR and indeed, deficiency of BRCA1 is accompanied
by abrogated formation of DSB-induced RAD51 foci and severely
reduced levels of HRR.
A variety of studies with cultured cell lines has revealed that
BRCA1 deficiency correlates with increased radiosensitivity to
killing, which derives from the associated HRR defects (Speit
and Trenz, 2004). These observations are further supported by
results showing decreased survival of irradiated BRCA1−/−mouse
embryonic fibroblasts exposed to IR and emphasize the central
role of HRR in the maintenance of genomic integrity. Notably,
more recent results suggest that inactivation of BRCA1 ubiquitin-
ligase activity up-regulates protein complexes involved in DNA
end-resection, causing elevated but aberrant HRR that under-
mines genomic instability (Drost et al., 2011; Dever et al., 2012).
Along these lines, C61G mutation in the BRCA1 gene is associ-
ated with complete loss of BRCA1 E3-ubiquitin-ligase function,
and disruption of the BRCA1/BARD1 complex, which results
in increased formation of RAD51 foci, and abnormal rate of
HRR (Drost et al., 2011). Such results explain the observation
that many sporadic BRCA1 deficient tumors develop radioresis-
tance – possibly through enhanced aberrant HRR that triggers
the function of the highly mutagenic B-NHEJ repair pathway
(see above).
Although the frequency of developing breast and ovarian can-
cer in individuals harboring mutations in the BRCA2 gene is lower
than in individuals harboringBRCA1mutations,BRCA2-deficient
patients have a 20-fold increased risk of developing prostate cancer
and about 10-fold increased risk to pancreatic and other form of
tumors like medulloblastomas and gliomas (Roy et al., 2012). This
suggests that despite common functions in DNA repair, BRCA1
and BRCA2 also have specific functions,which explains the distinct
behavior described above.
Breast cancer susceptibility gene 2 (BRCA2) is a 3418 amino
acids protein, harboring a specific domain consisting of about 30
degenerative BRC repeats that are responsible for the controlled
formation of RAD51 and DMC1 nucleoprotein filaments dur-
ing HRR and meiosis, respectively (Thorslund and West, 2007;
Roy et al., 2012). The BRC repeats exhibit subtle sequence varia-
tions allowing differential binding of RAD51 and mediating the
controlled displacement of RPA from ssDNA regions and the
nucleation of RAD51 monomers, which culminates with the for-
mation of a nucleoprotein filament (West, 2003) (Figure 2). The
importance of BRC repeats in BRCA2 function has been demon-
strated in patients with point mutations in this domain, which
develop breast and ovarian cancer with much higher frequency
than patients with mutations in other regions of the gene.
Available biochemical data suggest that the main function of
BRCA2 in DSB repair is to keep RAD51 in monomeric state and
to deliver RAD51 monomers to the resected DNA ends. As men-
tioned above, the potential of BRCA2 to bind RAD51 is tightly
regulated by CDK1 phosphorylation at Ser-3291, in the C-terminal
TR2 motif (Esashi et al., 2005, 2007), whose abrogation results
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in intolerable HRR and increased genomic instability, but which
might be exploited to enhance the killing potential of IR.
However, it is relevant to point out that all these well described
functions in DSB repair, are not sufficient to explain initiation
and progression of cancer in individuals with mutation in BRCA
genes. Certainly, it might be speculated that BRCA1 and BRCA2
are important for tumor suppression by virtue of their function
in HRR. Alternatively, it might be speculated that both proteins
suppress error-prone DSB repair pathways. A strong candidate for
such effects is B-NHEJ, whose involvement in DSB repair may
increase when HRR is abrogated. Moreover, reports that B-NHEJ
benefits from the presence of microhomology and the fact that
end-resection activities like CtIP and MRN complex facilitate B-
NHEJ (Xie et al., 2009; Lee-Theilen et al., 2011), support the idea
that B-NHEJ may exploit failures in HRR (see above). This is
especially true when limited resection of DNA ends is already
accomplished, as this will prevent the recruitment of key factors
of classical NHEJ. Another possibility, explaining the tumor sus-
ceptibility of BRCA-deficient patients is that the common genetic
alterations (e.g., BRCA1 or BRCA2 mutations) are regularly asso-
ciated with loss of wild-type p53 (Ramus et al., 1999), ATM
(Tommiska et al., 2008), or CHK2 (Cao et al., 2006). These addi-
tional alterations may permit cells to bypass checkpoint controls
and evade apoptosis, thereby commencing tumorigenesis.
Multiple studies link mutations in other DSB repair genes with
genomic instability and cancer predisposition. Prominent among
them, AT, AT like disorder (ATLD), and the NBS display muta-
tions in genes involved in the repair of DSBs by HRR. Thus, in AT
patients, ATM activity is abrogated and these individuals primarily
develop lymphoid malignancies. The ATLD and NBS syndromes
are associated with mutations in MRE11 and NBS1 genes, which
together with RAD50 form the MRN complex, involved in ini-
tiation of DNA end-resection for HRR (Stracker and Petrini,
2011).
HRR DEFICIENCY AS AN OPPORTUNITY IN CANCER
THERAPY: THE CONCEPT OF SYNTHETIC LETHALITY
DNA damaging agents used in cancer treatment induce a spectrum
of lesions in the DNA. These lesions are recognized by a variety
of cellular lesion-specific DNA repair pathways that operate to
remove them from the affected DNA molecules. It is commonly
accepted that DSBs are substrates for NHEJ (Lieber, 2010) and
HRR (San Filippo et al., 2008). The function of these DNA repair
pathways rescues malignant cells from death following exposure to
radiation or chemotherapeutic drugs and compromise thus cancer
treatment. It follows that inhibition of these repair processes, pref-
erentially in malignant cells, should enhance the efficacy of cancer
therapies based on killing cells by the induction of DSBs. Indeed,
evidence accumulates that success in cancer treatment often results
from DNA repair deficiencies in the cancer cells. Also, it has been
observed that when DSB repair deficient tumors develop resistance
to radiation or to DSB inducing drugs, they do so by improving
their DSB repair potential (Zwet et al., 2002).
Our present understanding of DSB induction and repair allows
us to postulate that combination of cytotoxic agents acting by
inducing DSBs with inhibitors of DSB repair will enhance tumor
cell killing – if this inhibition, or alternatively the induction of
DSBs, could be somehow preferentially targeted to tumor cells.
Similar arguments can be developed for other forms of DNA
damage and other pathways of DNA repair.
A number of inhibitors of DNA repair have been evaluated, or
are undergoing clinical trials, as potential anti-cancer chemicals.
Inhibitors of PARP-1 are of particular interest in treating heredi-
tary breast cancers occurring in patients who are carriers of BRCA1
or BRCA2 mutations (Bryant et al., 2005; Farmer et al., 2005). As
mentioned above, BRCA2 has been established as an integral com-
ponent of the HRR machinery, regulating the assembly of RAD51
filaments and facilitating strand exchange (Thorslund and West,
2007; Carreira and Kowalczykowski, 2009). Also HRR is impaired
in BRCA1 deficient cells.
Poly (ADP-ribose) polymerase 1 is known to be involved in
SSB repair, BER, and NER in association with XRCC1, LIG3,
PNK, PCNA, and FEN1 (Frouin et al., 2003; Okano et al., 2003).
PARP-1 is also involved in DSB repair (Küpper et al., 1995;
Tatsumi-Miyajima et al., 1999; Rudat et al., 2001), as well as in the
alternative/backup pathways of NHEJ (Wang et al., 2006; Iliakis,
2009). The combination of PARP-inhibitors with BRCA deficiency
provides a sound paradigm for the power of synthetic lethality
as a strategy for improving cancer treatment. Synthetic lethality
emerges when the combination of non-lethal mutations in two
or more genes operating in different metabolic pathways, or the
chemical inhibition of their products, causes cell death.
As expected from the basic premise of synthetic lethality, PARP-
1 is also effective in tumors with HRR defects deriving from genes
other than BRCA – sometimes referred to as“BRCAness”(de Gon-
zalez et al., 2011). Thus, deficiency inRAD51,RAD54,DSS1,RPA1,
NBS1, ATR, ATM, CHK1, CHK2, FANCD2, or FANCC genes was
found to be associated with synthetic lethality to PARP inhibition
(McCabe et al., 2006). These results confirm that the critical role
of BRCA1 and BRCA2 in HRR is the underlying reason for the
hyper-sensitivity to PARP-inhibitors of BRCA-deficient tumors.
Collectively, these results indicate that the approach of synthetic
lethality with PARP-1 inhibitors may prove useful for the treatment
of a wide range of tumors bearing HRR deficiencies, or displaying
properties of “BRCAness.”
An interesting synthetic lethal interaction has been established
between RAD52 and BRCA2. Loss of RAD52 function is synthet-
ically lethal with BRCA2 deficiency in human cancer cell lines
(Feng et al., 2011; Lok et al., 2012). This suggests that BRCA2 and
RAD52 provide alternative pathways for RAD51 mediated HRR in
mammalian cells. RAD52 also exerts other synthetic lethal pheno-
types: in chicken DT40 cells its inactivation is lethal when it occurs
together with inactivation of XRCC3 (Fujimori et al., 2001). On
the other hand, the viability of BRCA2-deficient DT40 cells is not
compromised by deletion of RAD52; rather, an epistatic relation-
ship between BRCA2 and RAD52 is suggested in these cells (Qing
et al., 2011). Combined defects in the BRCA2 ortholog Brh2 and
Rad52 generate a very subtle synthetic lethal phenotype inU.may-
dis (Kojic et al., 2008). These differences between human and other
species point to the care required in the generalization of syn-
thetic lethal interactions among species and restrict significantly
the spectrum of model organisms that can be used in their study.
Poly (ADP-ribose) polymerase 1 inhibition shows synergistic
interactions in combination with CHK1 inhibition and is thought
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to be mediated by the induction of apoptosis. CHK1 induced
phosphorylation of ERK1/2 and H2AX is abolished after PARP-
1 inhibition (Mitchell et al., 2010). However, the suppression of
HRR by CHK1 inhibition makes this kinase an excellent target for
synthetic lethality with PARP-1 inhibition also according to the
rational framework outlined above.
In agreement with this expectation, Hattori et al. established
a BRCA2 synthetic lethal RNAi screen, which identified CHK1
as a potential therapeutic target. Unexpectedly, though, CHK1
inhibitors failed to suppress the growth of BRCA2-deficient cells
in the context of KRAS activation and TP53 inactivation found
in pancreatic cancers (Hattori et al., 2011). This study extends the
above outlined precautions and emphasizes that synthetic lethal
interactions identified by in vitro screens may fail to show effective-
ness in the genetic context of specific cancer forms. Evidently, the
identification of synthetic lethal interactions and their exploitation
in cancer therapy requires extreme care, appropriate experimenta-
tion, and model systems closely resembling the tumor whose cure
is envisioned.
IMPACT ON RADIATION THERAPY OF ABNORMAL
EXPRESSION OF RAD51
Cancer cell lines show fluctuations in the level of expression of
genes involved in cell-cycle control and DDR. The variable expres-
sion of genes implicated in HRR, particularly overexpression of
RAD51, is seen in many tumors and is linked to increased radio-
or chemo-resistance. Moreover, a high level of RAD51 expression
is observed in a variety of tumor cell lines (Richardson, 2005) and
is associated with a poor outcome in the therapy of lung cancer
(Qiao et al., 2005).
In addition, mammalian cells with elevated RAD51 level show
genomic instability (Richardson et al., 2004), increased sponta-
neous recombination, and resistance to IR or to chemotherapeutic
agents (Vispe et al., 1998). All these findings associate increased
level of RAD51 with genomic instability and cancer development.
This is surprising considering that the functions of RAD51 in
HRR would predict the opposite, i.e., improved repair capacity.
Indeed, it has been shown that many leukemia-related disorders,
ovarian and breast carcinomas, as well as colon and rectal adeno-
carcinomas show, when irradiated, increased formation of RAD51
foci, which correlates with radioresistance (Raderschall et al., 2002;
Klein, 2008). Moreover, the HRR deficiency of cells lacking RAD51
paralogs or BRCA1 can be completely or partially rescued by
RAD51 overexpression (Schild and Wiese, 2010). Another report
shows that mRNA and protein levels of RAD51, XRCC3, RAD52,
and RAD54 genes are two to fivefold elevated in malignant prostate
cancer cell lines (Fan et al., 2004).
Interestingly, the high RAD51 levels in these tumors are not
mediated by RAD51 gene amplification; rather overexpression is
driven by aberrant oncogene related transcriptional activation.
This suggests problems with the regulation of DNA metabolism
in cancer cells. Major culprit for such behavior is the mutation
in the tumor suppressor gene p53, which was found to nega-
tively regulate RAD51 expression (Arias-Lopez et al., 2006; Hannay
et al., 2007). As p53 is the most frequently mutated gene in
human cancers (Hansen et al., 2003), a RAD51-related radio- and
chemo-resistance are likely consequences.
However, fluctuations in RAD51 level in tumor cells cannot be
completely explained by mutations in p53 gene. There are exam-
ples of RAD51 over expression in a functional p53 background,
suggesting a multilevel control of RAD51 expression. In these cases
high RAD51 level is associated with p53-dependent expression of
p21Waf-1, which affects the rate of BRCA1 transcription and the
activation of cell-cycle checkpoint response (Walsh et al., 2011).
Therefore, a strong G2 cell-cycle arrest is detected in RAD51-
overexpressing cells, which occurs through p21 mediated CDK1
inactivation (Raderschall et al., 2002).
It is relevant to speculate how increased RAD51 protein levels
confer radioresistance in tumor cells, especially when additional
mutations are generated in DNA repair genes that should make
them radiosensitive.
There are reports suggesting a positive correlation between
HRR and high levels of RAD51. Thus, p53 deficient Chinese
hamster ovary cells show elevated HRR when transfected with
a vector mediating overexpression of the RAD51 gene (Bertrand
et al., 2003). Furthermore, using an I-Sce-I-based reporter sys-
tem in mouse ES cells (Habrand and Le Pechoux, 2004), it was
found that RAD51 over expression increases HRR. Yet, in the latter
case increased HRR was associated with aberrant recombination
events including crossovers, chromosome translocations, as well
as multiple chromosome rearrangements and aneuploidy, suggest-
ing frequent abrogation of HRR and possibly the engagement of
B-NHEJ.
Thus, for successful HRR, RAD51 levels must be precisely
regulated; otherwise chromosomal instability may ensue. The cor-
respondence between RAD51 over expression, increased HRR,
and resistance to chemotherapeutic drugs suggest the possibil-
ity for developing treatment strategies based on RAD51 down
regulation – by specific inhibitors or RNAi.
RADIOSENSITIZATION BY CHEMOTHERAPEUTIC AGENTS
THROUGH INHIBITION OF HRR
As outlined above, intact or hyperactive HRR often correlates
with resistance to therapy, while defects in HRR, when not associ-
ated with sensitivity to treatment, offer opportunities for synthetic
lethality. It is timely, therefore, to explore means to inhibit HRR
in cells proficient in this repair pathway. The potential benefit of
this approach is reinforced by the observation that several com-
pounds with antitumor activity and wide application in the clinic
also inhibit HRR, and thus generate opportunities for synergistic
interactions.
Radiosensitizing effects, in addition to their cytotoxic action,
have been demonstrated for many chemotherapeutic drugs.
Although the radiosensitizing effects of some of those drugs, e.g.,
5-fluorouracil (5-FU), have been known for decades, the underly-
ing mechanisms remain largely unclear. However, the number of
radiosensitizers that are found to inhibit HRR is growing. These
include nucleoside and base analogs like gemcitabine (Wachters
et al., 2003), TAS-106 (Meike et al., 2011), and gimeracil (Tak-
agi et al., 2010) as well as other antimetabolites like pentoxi-
fylline and caffeine (Asaad et al., 2000; Böhm, 2006). Furthermore
the ATR inhibitor VE-821 (Prevo et al., 2012) and the CHK1/2
inhibitor AZD7762 (Morgan et al., 2010) have been reported to
inhibit HRR.
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There is also a growing list of inhibitory substances and
therapeutics, which are less directly linked to DNA metabolism
and damage response, but which are suggested to radiosensi-
tize tumor cells by inhibiting HRR. These include the tyrosine
kinase inhibitors imatinib and erlotinib (Chinnaiyan et al., 2005;
Li et al., 2008; Choudhury et al., 2009), the HDAC inhibitor
PCI-24781 (Adimoolam et al., 2007), the proteasome inhibitor
MG132 (Murakawa et al., 2007), and 17-AAG, an inhibitor
of HSP90 (Noguchi et al., 2006). Moreover, mild hyperther-
mia was found to inhibit HRR and to sensitize cells to PARP-
inhibitors (Krawczyk et al., 2011; Bergs et al., 2013). In addi-
tion specific inhibitors of HRR are now being identified in spe-
cialized screens, like BO2, which inhibits the RAD51 activity
in strand exchange (Huang et al., 2012) and RI-1, a specific
inhibitor of RAD51 that covalently binds to RAD51 and sup-
presses RAD51 nucleoprotein filament formation (Budke et al.,
2012).
Finally, it should be pointed out that IR, but also many
widely used chemotherapeutic compounds induce large amounts
of base damage, or generate replication errors that require mis-
match repair for correction. As a result, it is possible to signifi-
cantly improve cancer treatment by developing strategies for the
simultaneous inhibition during treatment of some of these repair
pathways, or by exploiting genetic defects in cancer cells in these
repair pathways (Kinsella, 2009).
CONCLUSION
It is evident from the above outline that a wealth of information
and a variety of approaches are evolving that promise to improve
the outcome of radiation therapy beyond the precise and more spe-
cific targeting of the radiation dose to the tumor. These approaches
are aided and accelerated by rapid advances in synthetic chemistry
and in protein structure information. As a result, they are likely to
mature quickly and to open a new era of opportunities in radiation
therapy. Radiation oncologists are likely to benefit significantly
from these developments, if they closely follow them and quickly
adapt them to the requirements of treatment of human tumors
by IR.
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APPENDIX
Table A1 | Used abbreviations.
53BP1 p53 binding protein 1
5-FU 5-fluorouracil
ATM Ataxia telangiectasia mutated
ATR ATM and Rad3 related
BARD1 BRCA1-associated RING domain 1 protein
BIR Break induced replication
BLM Bloom’s syndrome helicase
B-NHEJ Backup non-homologous end-joining
BRCA1 Breast cancer susceptibility gene 1
BRCA2 Breast cancer susceptibility gene 2
CDKs Cyclin dependent kinases
CHK1/2 Checkpoint kinase 1/2
CK2 Casein kinase 2
CML Chronic myelogenous leukemia
CtIP C-terminal binding protein 1 interacting protein
DDR DNA damage response
dHJ Double Holliday junction
D-loop Displacement loop
DNA-PKcs DNA dependent protein kinase catalytic subunit
D-NHEJ DNA-PKcs dependent non-homologous end-joining
DSBs Double-strand breaks
EXO1 Exonuclease 1
FEN1 Flap endonuclease 1
HDAC Histone deacetylases
HRR Homologous recombination repair
HU Hydroxyurea
IR Ionizing radiation
LIG1 DNA ligase 1
LIG3 DNA ligase 3
LIG4 DNA ligase 4
LOH Loss of hetorozygosity
MAPK Mitogen activated protein kinases
MRE11 Meiotic recombination 11
MRN MRE11/RAD50/NBS1
NBS1 Nijmegen breakage syndrome 1
NHEJ Non-homologous end-joining
PARI PCNA-associated recombination inhibitor
PARP-1 Poly (ADP-ribose) polymerase 1
PCNA Proliferation cell nuclear antigen
PFGE Pulse-field gel electrophoresis
PI3K Phosphatidyl inositol 3-OH kinases
PLK1 Polo like kinase 1
PNK Polynucleotide kinase phosphatase
PTMs Post-translational modifications
RPA Replication protein A
RTEL1 Regulator of telomere elongation helicase 1




SUMO Small ubiquitin like modifiers
WRN Werner syndrome helicase
XLF XRCC4 like factor
XRCC1 X-ray cross complemented 1
XRCC4 X-ray cross complemented 4
Frontiers in Oncology | Radiation Oncology May 2013 | Volume 3 | Article 113 | 18
